Clinical Trial Results:
A 12-week, double-blind, randomized, placebo-controlled, Phase 2 study to evaluate the effects of two doses of MBX-8025 in subjects with Primary Biliary Cirrhosis (PBC) and an inadequate response to ursodeoxycholic acid (UDCA).
Summary
|
|
EudraCT number |
2015-002698-39 |
Trial protocol |
GB DE PL |
Global end of trial date |
01 Jul 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
26 Jul 2017
|
First version publication date |
26 Jul 2017
|
Other versions |
|
Summary report(s) |
Synopsis |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
CB8025-21528
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02609048 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
CymaBay Therapeutics, Inc.
|
||
Sponsor organisation address |
7999 Gateway Blvd, Suite 130, Newark, United States, CA94560
|
||
Public contact |
Karen Benson, CymaBay Therapeutics, Inc. , Kbenson@cymabay.com
|
||
Scientific contact |
Pol Boudes, CymaBay Therapeutics, Inc. , Pboudes@cymabay.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
01 Jul 2016
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
17 Jun 2016
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
01 Jul 2016
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective of this study is to evaluate the effect of seladelpar on alkaline phosphatase (AP) levels.
|
||
Protection of trial subjects |
Participation in the study is voluntary. Subjects can refuse to participate or stop at any time without stating a reason. Withdrawal will not affect access to other medical care to which the subject would otherwise be entitled.
|
||
Background therapy |
Ursodeoxycholic acid (UDCA) was continued to be taken by subjects in all treatment arms at the same dose during the study. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
04 Nov 2015
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Canada: 4
|
||
Country: Number of subjects enrolled |
United States: 20
|
||
Country: Number of subjects enrolled |
United Kingdom: 9
|
||
Country: Number of subjects enrolled |
Germany: 8
|
||
Worldwide total number of subjects |
41
|
||
EEA total number of subjects |
17
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
35
|
||
From 65 to 84 years |
6
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||
Recruitment details |
Enrollment period began in November 2015. On 26-May-16, the sponsor decided to terminate the study for safety and efficacy reasons. | ||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||
Screening details |
Subjects are male or female with diagnosed PBC by at least two of the following criteria: History of AP above ULN for at least 6 months; Positive AMA titers or positive PBC-specific antinuclear antibodies; documented liver biopsy result consistent with PBC. Subjects are on a stable and recommended dose of UDCA for 12 months and have AP ≥ 1.67 ×ULN. | ||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||
Period 1 title |
Baseline period
|
||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Carer, Assessor | ||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||
Arm title
|
Baseline / seladelpar 50 mg | ||||||||||||||||||||||||||||
Arm description |
4 weeks Baseline Period / seladelpar 50 mg | ||||||||||||||||||||||||||||
Arm type |
Baseline evaluations | ||||||||||||||||||||||||||||
Investigational medicinal product name |
Seladelpar 50 mg
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
MBX-8025 50 mg
|
||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Not applicable
|
||||||||||||||||||||||||||||
Arm title
|
Baseline / seladelpar 200 mg | ||||||||||||||||||||||||||||
Arm description |
4 weeks Baseline Period / seladelpar 200 mg | ||||||||||||||||||||||||||||
Arm type |
Baseline evaluations | ||||||||||||||||||||||||||||
Investigational medicinal product name |
Seladelpar 200 mg
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
MBX-8025 200 mg
|
||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Not applicable
|
||||||||||||||||||||||||||||
Arm title
|
Baseline / placebo | ||||||||||||||||||||||||||||
Arm description |
4 weeks Baseline Period / placebo | ||||||||||||||||||||||||||||
Arm type |
Baseline evaluations | ||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
Placebo
|
||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Not applicable
|
||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
Period 2
|
|||||||||||||||||||||||||||||
Period 2 title |
Double blind treatment and follow-up
|
||||||||||||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Carer, Assessor | ||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||
Arm title
|
50 mg | ||||||||||||||||||||||||||||
Arm description |
12-weeks treatment period with seladelpar 50 mg daily, followed by 2 week follow-up period | ||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||
Investigational medicinal product name |
Seladelpar 50 mg
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
MBX-8025 50 mg
|
||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Seladelpar 50 mg taken orally once a day
|
||||||||||||||||||||||||||||
Arm title
|
200 mg | ||||||||||||||||||||||||||||
Arm description |
12-weeks treatment period with seladelpar 200 mg daily, followed by 2 week follow-up period | ||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||
Investigational medicinal product name |
Seladelpar 200 mg
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
MBX-8025 200 mg
|
||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Seladelpar 200 mg taken orally once a day
|
||||||||||||||||||||||||||||
Arm title
|
placebo | ||||||||||||||||||||||||||||
Arm description |
12-weeks treatment period with placebo daily, followed by 2 week follow-up period | ||||||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Placebo taken orally once a day
|
||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||
Reporting group title |
Baseline period
|
||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Baseline / seladelpar 50 mg
|
||
Reporting group description |
4 weeks Baseline Period / seladelpar 50 mg | ||
Reporting group title |
Baseline / seladelpar 200 mg
|
||
Reporting group description |
4 weeks Baseline Period / seladelpar 200 mg | ||
Reporting group title |
Baseline / placebo
|
||
Reporting group description |
4 weeks Baseline Period / placebo | ||
Reporting group title |
50 mg
|
||
Reporting group description |
12-weeks treatment period with seladelpar 50 mg daily, followed by 2 week follow-up period | ||
Reporting group title |
200 mg
|
||
Reporting group description |
12-weeks treatment period with seladelpar 200 mg daily, followed by 2 week follow-up period | ||
Reporting group title |
placebo
|
||
Reporting group description |
12-weeks treatment period with placebo daily, followed by 2 week follow-up period |
|
|||||||||||||||||
End point title |
To evaluate the effect of seladelpar on AP levels | ||||||||||||||||
End point description |
|||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
End of treatment - Week 12
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
effect of seladelpar on AP levels | ||||||||||||||||
Statistical analysis description |
ANCOVA model
|
||||||||||||||||
Comparison groups |
placebo v 50 mg v 200 mg
|
||||||||||||||||
Number of subjects included in analysis |
35
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [1] | ||||||||||||||||
Method |
ANCOVA | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Notes [1] - LS mean difference 50 mg vs. placebo: P < 0.0001. LS mean difference 200 mg vs. placebo: P < 0.0001. LS mean difference 50 mg vs. 200 mg: P = 0.1167. |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
An AE will be recorded any time after the time of signed ICF and captured until the end-of-study visit.
|
||
Adverse event reporting additional description |
Please see attached synopsis
|
||
Assessment type |
Systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
MedDRA | ||
Dictionary version |
18.1
|
||
Frequency threshold for reporting non-serious adverse events: 5% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: Justification: Please see attached synopsis |
|
|||||||
Substantial protocol amendments (globally) |
|||||||
Were there any global substantial amendments to the protocol? Yes | |||||||
Date |
Amendment |
||||||
04 Sep 2015 |
The protocol was amended on 4 September 2015 to create Version 3.0. The main changes to the protocol were as follows:
- Tightened the requirements for contraceptive use during the study, including requiring the use of contraception for 90 days after the last dose of study medication because the effect of MBX‑8025 on pregnant women and fetuses has not been characterized.
- Introduced stratification by geographic region in the efficacy analyses. |
||||||
12 Oct 2015 |
The protocol was amended on 12 October 2015 to create Version 4.0. The main changes to the protocol were as follows:
- Reporting of the severity of AEs was updated to reflect the use of NCI CTCAE Version 4.
- Serum creatinine above the ULN was added to the study exclusion criteria because the target population for this study is early-stage PBC subjects. In early stages of PBC, patients have normal serum creatinine levels.
- The current use of fibrates, including fenofibrates or simvastatin was added to the study exclusion criteria because of their potential to confound the primary efficacy analysis.
- ECGs were moved to be performed 60-90 minutes after dosing to coincide with the time of the maximum plasma MBX-8025 concentration.
Changes specific to the UK were made to Protocol Version 4.0 on 22 October 2015 to create Version 4.1 per the request of regulatory authorities. The main UK-specific changes to the protocol were as follows:
- Added serum pregnancy tests for women of childbearing potential during the baseline period (within 2 weeks of Visit 2) and at each visit during the double-blind treatment period.
- Specified that female subjects who became pregnant during the study were to be discontinued from the study. |
||||||
Interruptions (globally) |
|||||||
Were there any global interruptions to the trial? Yes | |||||||
|
|||||||
Limitations and caveats |
|||||||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||||||
Because the study was discontinued before its completion, the interpretation of the results is limited by the small sample size and some imbalance in baseline characteristics. |